This article is more than 5 years old. Information may no longer be current.

Meta-analysis: Allogeneic stem cell transplant beneficial in intermediate-, poor-risk AML

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

According to data from a meta-analysis, allogeneic stem cell transplantation significantly improved relapse-free survival and OS in patients with intermediate- and poor-risk acute myeloid leukemia in complete remission compared with nonallogeneic stem cell transplantation. However, allogeneic stem cell transplantation did not demonstrate benefit in good-risk AML in first complete remission.

Researchers conducted a systematic review and meta-analysis to measure the benefit allogeneic stem cell transplantation provided in terms of relapse-free survival and OS in AML in first complete remission and for good-, intermediate- and poor-risk AML. The analysis identified 24 trials with 6,007 patients who were assigned to allogeneic SCT vs. non-allogeneic SCT. Trials reported relapse-free survival and OS.

According to a fixed-effects meta-analysis, for allogeneic stem cell transplantation for AML in first remission, the HR of relapse or death was 0.80 (95% CI, 0.74-0.86) compared with non-allogeneic stem cell transplantation. Relapse-free survival benefit was higher for allogeneic stem cell transplantation in poor-risk (HR=0.69; 95% CI, 0.57-0.84) and intermediate-risk AML (HR=0.76; 95% CI, 0.68-0.85) compared with non-allogeneic stem cell transplantation. However, allogeneic stem cell transplantation did not demonstrate benefit in good-risk AML (HR=1.06; 95% CI, 0.80-1.42).

In AML in first complete remission, the HR for death with allogeneic stem cell transplantation was 0.90 (95% CI, 0.82-0.97). Allogeneic stem cell transplantation was associated with a significant benefit to OS in poor-risk (HR=0.73; 95% CI, 0.59-0.90) and intermediate-risk AML (HR=0.83; 95% CI, 0.74-0.93). However, there was no significant benefit for good-risk AML (HR=1.07; 95% CI, 0.83-1.38).

Koreth J. JAMA. 2009;301:2349-2361.